Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients
NCT ID: NCT01215513
Last Updated: 2013-05-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
127 participants
INTERVENTIONAL
2010-09-30
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer
NCT01071915
Safety and Efficacy of Firmagon® (Degarelix) for Injection
NCT02886598
An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer
NCT00215683
An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer
NCT02015871
Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer
NCT00738673
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Degarelix
Degarelix
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Degarelix
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has completed the 7-month main trial, FE200486 CS42
Exclusion Criteria
* A patient may also not be entered into the CS42A trial at the discretion of the investigator due to safety or lack of efficacy concerns (LH or PSA response) in the CS42 trial.
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ferring Pharmaceuticals Korea, Ltd.
OTHER
Ferring Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Development Support
Role: STUDY_DIRECTOR
Ferring Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Korea University Hospital
Seoul, Anam-dong, Seongbuk-gu, South Korea
Seoul St. Mary's Hospital
Seoul, Banpo-dong, Seocho-gu, South Korea
Kyoungbuk National University Hospital
Daegu, Daegu, South Korea
Yonsei University Health System Gangnam Sevrance
Seoul, Eonguro, Gangnam-gu, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Hallym University Sacred Heart Hospital
Pyungchon, Gyunggi-do, South Korea
Pusan National University Yangsan Hospital
Mulgeum-eup, Gyungnam, South Korea
Samsung Medical Center
Seoul, Ilwon-dong, Kangnam-gu, South Korea
Asan Medical Center
Seoul, Pungnap-2-dong, Songpa-gu, South Korea
Yonsei University Health System (Sevrance Hospital)
Seoul, Seongsanno, Seodaemun-gu, South Korea
Seoul National University Hospital
Seoul, Yeongeon-dong, Chongno-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FE200486 CS42A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.